Corbus Pharmaceuticals Holdings, Inc.
NCM: CRBPLive Quote
About Corbus Pharmaceuticals Holdings, Inc.
Healthcare
Biotechnology
Corbus Pharmaceuticals Holdings, Inc., a clinical stage company, develops and commercializes therapeutics for cancer and obesity. Its pipeline includes CRB-701, an antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload of monomethyl auristatin E; and CRB-913, a peripherally restricted cannabinoid type-1 receptor inverse agonist for the treatment of obesity. The company was incorporated in 2009 and is headquartered in Norwood, Massachusetts.
📊 Fundamental Analysis
Corbus Pharmaceuticals Holdings, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -54.2%, which indicates that capital utilization is currently under pressure.
At a current price of $9.80, CRBP currently sits at the 28th percentile of its 52-week range (Range: $5.68 - $20.56).
🏥 Financial Health
🔴
Profit Margin
Weak
🔴
Debt/Equity
Elevated
🔴
Return on Equity
Weak
🔴
Beta (Risk)
High Volatility
Key Financials
Market Cap
$142.66M
Trailing P/E
--
Forward P/E
-2.00
Beta (5Y)
2.79
52W High
$20.56
52W Low
$5.68
Avg Volume
194K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App